Clinical trials of antiepileptic drugs performed in the private practice setting.
Clinical trials of antiepileptic drugs (AEDs) are usually performed only in major teaching centers, thus ignoring the very real contribution available from private practice. The relation between the consultant and the referring family physician is often much closer in private practice, allowing much earlier recruitment of de novo patients into clinical trials. Between October 1988 and February 1992, 50 subjects were entered into various clinical trials including gabapentin (both an open add-on trial and parallel-arm add-on study in generalized epilepsies), vigabatrin (placebo-controlled cross-over study in focal epilepsies), and lamotrigine (both placebo-controlled cross-over add-on studies and parallel-arm comparative monotherapy study in newly diagnosed patients with epilepsy). All these trials were coordinated in private neurologic practice in Sydney, Australia, as part of either national or international multicenter AED studies. The experience demonstrated the improved ease of recruitment and patient liaison available in the private sector. It also highlighted the very real logistic problems, such as the need for a noninstitutional-based ethics committee, the training of support staff and a modified primary information resource system. Inclusion of private practice centers in clinical trials demonstrates the potential for improved patient recruitment and administrative management, especially in studies requiring newly diagnosed patients.
Beran
R G
RG
Tilley
M
M
D000085:Acetates / Q000627:therapeutic use; D000588:Amines; D000614:Aminocaproates / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use*; D001315:Australia; D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards / Q000706:statistics & numerical data; D003509:Cyclohexanecarboxylic Acids; D004827:Epilepsy / Q000188:drug therapy*; D004992:Ethics, Medical; D000077206:Gabapentin; D006801:Humans; D000077213:Lamotrigine; D015337:Multicenter Studies as Topic; D009462:Neurology; D011331:Private Practice; D014227:Triazines / Q000627:therapeutic use; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000614:Aminocaproates; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D014227:Triazines; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D020888:Vigabatrin; D000077213:Lamotrigine